Skip to main content

Table 1 Baseline characteristics of the study population

From: Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

  SSc-PAH SSc Idiopathic PAH Healthy control
N 18 21 15 14
Men/woman (Nof patients) 2/16 3/18 5/10 3/11
Disease duration (years ± SD 21.1 ± 7.6 19.1 ± 9.0 20.0 ± 10  
Age (mean, years ± SD) 69.8 ± 8.0 60.5 ± 9.3 62.5 ± 14.6 63.7 ± 10.1
lcSSc/dcSSc (Nof patients) 5/13 7/14   
ACA/Scl70 (Nof patients) 5/13 7/14   
Digital ulcers (Nof patients) 2 1   
sPAP eco 73.1 ± 16.6 23.3 ± 4.4 68.7 ± 20.5  
mPAP RHC 43.0 ± 10.6   49.9 ± 21.0  
mRSS in dcSSc (mean ± SD) 16.8 ± 2.4 10.6 ± 7.1   
mRSS in lcSSc (mean ± SD) 3.6 ± 2.5 3.9 ± 2.3   
Prostanoid Not Not Not Not
Calcium-channel blockers Not Not Not Not
Phosphodiestererase-5 inhibitors Not Not Not Not
Endothelin-1 receptors antagonists Not Not Not Not
Vasoactive therapies Not Not Not Not
  1. ACA anti-centromere antibodies, dcSSc diffuse cutaneous SSc, lcSSc limited cutaneous SSc, mPAP RHC mean pulmonary artery pressure measured by RHC, mRSS modified Rodnan skin score, N number, PAH Pulmonary arterial hypertension, RHC right heart catheterization, SD standard deviation, sPAP eco systolic pulmonary artery pressure measured by echocardiography, SSc systemic sclerosis